Efficacy of Benralizumab and Clinical Course of IgG4 in Eosinophilic Granulomatosis With Polyangiiti

摘要

Eosinophilic granulomatosis with polyangiitis (EGPA) presents clinically as a systemic eosinophilic disease with asthma and eosinophilia [1]. It causes eosinophilic necrotizing granulomatous inflammation, which damages the respiratory organs, and necrotizing angiitis, which affects the small blood vessels. Systemic corticosteroids are generally used as the first-line treatment to attain remission in EGPA, although they cannot be used for long-term therapy owing to their potential adverse effects. Mepolizumab, a biologic interleukin (IL) 5 antibody, has been shown to suppress recurrence of EGPA [2]; however, half of the patients studied did not achieve remission, even when mepolizumab was coadministered with corticosteroids.